(For) all our vaccines, we are looking at right now..(we) are targeting 2-8 degree because our logistics are worked out on that basis and we are working on that, DBT secretary Renu Swarup said at a press briefing

Poonawalla says Covishield shows efficacy level of 95 per cent provided two shots are taken after a gap of 2-3 months; AstraZeneca will make that public with documentation soon, he adds

COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate, named UB-612; vaccine's main advantage is that it uses normal refrigeration for distribution

SII had earlier said its vaccine candidate showed 90 per cent efficacy rate at a full dose plus a half dose regimen, while a 62 per cent efficacy rate at full two-dose regimen

GSK said phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years but there was an insufficient response in older adults

In trials conducted in the US, four out of 21,720 participants who received the Pfizer vaccine suffered Bell's palsy, but this is consistent with the trend in a random population

UK's Medicines and Healthcare products Regulatory Agency issued the advisory after two NHS workers developed allergic reactions shortly after receiving the Pfizer vaccine; they are stable now

On December 2, the UK became the first nation to approve Pfizer-BioNTech vaccine against COVID-19 for emergency use; Bahrain has also approved vaccine candidate 'BNT162b2'. India decision on vaccine could come this week

\"During this pandemic phase, Pfizer will supply this vaccine only via government contracts based on agreements with respective govt authorities & following regulatory authorization or approval\", the US pharma firm said

Pfizer Inc submitted application to DCGI seeking emergency use authorisation on Dec 4; also seeks permission to import vaccine for sale and distribution in India

On December 2, the UK became the first country in the world to approve Pfizer and BioNTech coronavirus candidate BNT162b2 after the Medicines and Healthcare Products Regulatory Agency found the jab safe for widespread rollout

Study says anti-bodies declined slightly over time but remained elevated in all participants even 3 months after vaccination. NIAID director Anthony Fauci and other infectious diseases experts say it is possible that our bodies would remember virus and produce more anti-bodies if exposed to the virus again

Pfizer and BioNTech vaccine: The UK has already ordered 40 million doses of the Pfizer vaccine to vaccinate its 20 million population, of which around 10 million doses will be available soon

There are only five companies that have given preliminary data about how effective their vaccines could be to fight against coronavirus. These five companies include Pfizer-BioTech, Moderna Inc, Oxford University-AstraZeneca Plc, and Gamaleya Institute

As coronavirus cases continue to rise, the UK plans to move fast in the approval process and clearance to Pfizer and BioNTech SE could come by next week

New vaccines are rarely certified for efficacy above 90 per cent. Their efficacy improves as millions are vaccinated over decades. In fact, most vaccines get certified in the 40-60 per cent efficacy band

SII has partnered with AstraZeneca and Oxford University for the manufacturing and distribution of its COVID-19 vaccine candidate 'Covishield' in India and other countries

Vardhan says it makes no sense to consider Pfizer as pharma major is yet to get approval in the US. After requisite approvals, US pharma major will have to cater to needs of its own country's population first

Earlier on Monday, the Oxford-AstraZeneca team announced that one of the dosing regimens of the vaccine might be 90% effective in preventing COVID-19 infection

The panel-led by Dravida Munnetra Kazhagam (DMK) lawmaker Kanimozhi Karunanidhi will hear officials of pharmaceutical departments on the status of the COVID-19 vaccine